EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply

Wendy Y Chen, Karla V Ballman, Michelle D Holmes

JAMA · 2024

DOI: 10.1001/jama.2024.15500 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Wendy Y Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, Massachusetts. Hauptthemen laut MEDLINE: Breast Neoplasms, Aspirin. Die Arbeit nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAspirinHumansFemaleChemotherapy, AdjuvantAnti-Inflammatory Agents, Non-Steroidal

Substanzen

AspirinAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Mayo Clinic, Rochester, Minnesota.
  • Brigham and Women's Hospital, Boston, Massachusetts.

Zitieren

APA

Chen, W. Y., Ballman, K. V., & Holmes, M. D. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply. JAMA. https://doi.org/10.1001/jama.2024.15500

Vancouver

Chen WY, Ballman KV, Holmes MD. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply. JAMA. 2024. doi:10.1001/jama.2024.15500

BibTeX
@article{Chen2024,
  author = {Chen, Wendy Y and Ballman, Karla V and Holmes, Michelle D},
  title = {Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer—Reply},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.15500}
}
Kostenlos starten →